PK and PD Study of NPI-001 and Cysteamine Bitartrate

Exclusion Criteria

• •1. Have undergone kidney transplantation.
• •2. Are receiving dialysis treatment.
• •3. History of significant hypersensitivity to NAC or any ingredient of NPI-001 oral solution.
• •4. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the 30 days prior to Day 1.
• •5. Inability to provide blood samples, including difficulty with venous access.
• •6. Subjects who, in the opinion of the Investigator and/or Sponsor (or designee), should not participate in this study.